Karyopharm Therapeutics Q1 2024 GAAP EPS $(0.32) Beats $(0.33) Estimate, Sales $33.126M Miss $34.473M Estimate
Karyopharm Therapeutics Q1 2024 GAAP EPS $(0.32) Beats $(0.33) Estimate, Sales $33.126M Miss $34.473M Estimate
Karyopharm Therapeutics 2024年第一季度公认会计准则每股收益美元（0.32）超过预期（0.33）美元，销售额3312.6万美元低于预期的344.73亿美元
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.33) by 3.03 percent. This is a 6.67 percent decrease over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $33.126 million which missed the analyst consensus estimate of $34.473 million by 3.91 percent. This is a 14.40 percent decrease over sales of $38.698 million the same period last year.
Karyopharm Therapeutics（纳斯达克股票代码：KPTI）公布的季度亏损为每股0.32美元，比分析师普遍预期的0.33美元（0.33美元）高出3.03％。这比去年同期每股亏损0.30美元（0.30美元）下降了6.67％。该公司公布的季度销售额为3312.6万美元，比分析师普遍预期的347.3万美元低3.91％。这比去年同期的3,869.8万美元的销售额下降了14.40％。